Skip to main content
Clinical Trials/CTRI/2021/02/031271
CTRI/2021/02/031271
Completed
未知

A Multicentric, cross-sectional, non interventional survey to understand the demographics, diagnosis, clinical presentation and management of patients with Dyspepsia in India. - POWER

Dr Reddys Laboratories Ltd0 sites3,739 target enrollmentTBD

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
Dr Reddys Laboratories Ltd
Enrollment
3739
Status
Completed
Last Updated
3 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
October 18, 2021
Last Updated
3 years ago
Study Type
Observational

Investigators

Eligibility Criteria

Inclusion Criteria

  • 1 Patients of either sex aged 18 years and above.
  • 2 Willing and able to give inform consent.
  • 3 Patient with clinical diagnosis of Dyspepsia

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Not Applicable
This study is to understand the Clinical Characters, Social & demographic Profile, and Treatment Patterns in Patients with Bipolar Depression in India
CTRI/2018/09/015861Abbott Healthcare Pvt Ltd574
Not yet recruiting
Not Applicable
Observational study of pregnancy kit for rapid detection of pregnancy.
CTRI/2023/11/059697Mankind Pharma Limited
Completed
Not Applicable
Study to evaluate prevalence of Non-Alcoholic Steatohepatitis diagnosed through transient elastography & evaluate performance of various non-invasive liver fibrosis scores in Indian type 2 diabetes mellitus patientsHealth Condition 1: E116- Type 2 diabetes mellitus with other specified complications
CTRI/2023/08/056193Dr Debmalya Sanyal351
Completed
Not Applicable
Observational study of pregnancy kit for rapid detection of pregnancy.
CTRI/2022/03/041516Mankind Pharma Limited Mankind Pharma Limited
Active, not recruiting
Not Applicable
This is a clinical study to investigate how well Biostate works in treatment of male patients below the age of 12 years who have a clotting factor deficiency that is aggravated by the development of antibodies. The antibodies are directed against the clotting factor that is given for replacement therapy and usually make therapy unsuccessful. The treatment used in this study is called immune tollerance therapy.Male paediatric subjects with Haemophilia A who developed high titre antibodies to human coagulation Factor VIIIMedDRA version: 14.1Level: LLTClassification code 10018941Term: Haemophilia NOSSystem Organ Class: 10010331 - Congenital, familial and genetic disordersTherapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]
EUCTR2010-020113-85-ITCSL BEHRING S.P.A.20